rabbit antibodies against erk cat#4695  (Cell Signaling Technology Inc)

Journal: Frontiers in Pharmacology

Article Title: Astragaloside IV improves slow transit constipation by regulating gut microbiota and enterochromaffin cells

doi: 10.3389/fphar.2023.1196210

Figure Lengend Snippet: Immunohistochemical Analysis of CD117 and CGA Expression in the Colon and Western blot Analysis from Piezo2, TPH1, p-p38, p38, p-RRK, ERK, Caspase-3 p 12 and ACTB (A, B) Immunohistochemical staining of CD117 (A) and CGA (B) in the ileum, cecum, and colon tissues with corresponding average optical density (AOD) of the muscle layer in each tissue. (C) Western blot analysis of colon tissue from normal control group (Nor), loperamide-treated group (Lop), and astragaloside IV-treated group (AS). Nor: normal control group; Lop: loperamide; AS: astragaloside IV; ACTB: beta actin. Significance was determined as p < 0.05 and denoted as * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Article Snippet: The primary antibodies used were as follows: ERK (Cat.#4695) (1:2000), phospho-ERK (p-ERK) (Cat.#4370) (1:2000), p38 MAPK (Cat.#54470) (1:2000), and phosphor-p38 (p-p38) MAPK (Cat.#4511) (1:2000) from Cell Signaling Technology (United States); Piezo2 (Cat.#NBP1-78624, Novus Bioicals, Beijing, China) (1:500); TPH1 (Cat. #BS3727, Bioworld, Nanjing, China) (1:500); Caspase-3 (Cat.#A5013) (1:2000), Caspase-3 p12 (Cat.#A5357) (1:2000), Bcl-2 (Cat.#A5010) (1:2000), and Bax (Cat.#A5131) (1:2000) from Bimake, Houston, Texas, United States. β -Actin (Cat.#BS6007m) (1:5000) was used as the internal reference gene.

Techniques: Immunohistochemical staining, Expressing, Western Blot, Staining, Control

Journal: Frontiers in Cell and Developmental Biology

Article Title: Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K

doi: 10.3389/fcell.2015.00047

Figure Lengend Snippet: Inhibition of the Raf/MEK/ERK pathway is sufficient to partially restore CD24 mRNA but not protein expression in RasV12 cells . (A–C) RasV12 cells were treated for 16 h with DMSO (D) , or U0126 (U) and/or LY294002 (LY). (A) Western blot analysis was performed to detect phosphorylated ERK (P-ERK), and phosphorylated Akt (P-Akt). Total ERK and total Akt were used as loading controls. Molecular mass standards are shown in the right of each image. One representative experiment from three replicates is shown. CD24 mRNA expression in Control and RasV12 cells was determined by (B) RT-PCR and (C) RT-qPCR. RPLP0 was used as the loading and normalization control. Significance was determined by One-Way ANOVA with Tukey Honest Significant Difference post-hoc analysis, * P < 0.05. (D) Surface CD24 protein was determined by flow cytometry with Control or RasV12 cells treated for 24 h as above. One representative histogram of isotype (Iso) and CD24-stained cells is shown. (E) Quantification of CD24 surface protein expression as mean ± s.e.m percentage of CD24 + cells. Significance was determined by student's t -test, n = 4, − P < 0.1; ** P < 0.01.

Article Snippet: Primary antibodies to detect phosphorylated ERK (Cat #9101), phosphorylated Akt (Cat #9271), total ERK (Cat #4695), and total Akt (Cat #9272) were obtained from Cell Signaling Technologies, Inc (Danvers, MA, USA).

Techniques: Inhibition, Expressing, Western Blot, Control, Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Staining